Tracer library / [177Lu]Lu-EB-TATE

[177Lu]Lu-EB-TATE

Also written as [Lu-177]Lu-EB-TATE; Lu-177-EB-TATE

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: —
Syntheses indexed: 0

Neuroendocrine neoplasms Peptide receptor radionuclide therapy

What it is

Compound class: EB-TATE (Evans blue-conjugated somatostatin analog, SSTR2 agonist)
Target / mechanism: SSTR2 agonist targeting somatostatin receptor 2, with albumin-binding Evans blue moiety for prolonged retention PMID 40177560
Clinical application: Peptide receptor radionuclide therapy (PRRT) for metastatic/advanced neuroendocrine tumors PMID 40177560
Theranostic pair: —

Published syntheses

No synthesis has been parsed for this agent yet.

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study.
2025 · Acta Pharm Sin B · Prospective

Need this precursor?We can point you to suppliers for [177Lu]Lu-EB-TATE, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40177560: 'EB-TATE'.